Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/20399Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Papadopoulos, I. A. | en |
| dc.contributor.author | Georgiou, P. E. | en |
| dc.contributor.author | Katsimbri, P. P. | en |
| dc.contributor.author | Drosos, A. A. | en |
| dc.date.accessioned | 2015-11-24T19:07:04Z | - |
| dc.date.available | 2015-11-24T19:07:04Z | - |
| dc.identifier.issn | 0770-3198 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/20399 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Female | en |
| dc.subject | Fibromyalgia/*drug therapy/metabolism | en |
| dc.subject | Humans | en |
| dc.subject | Indoles/*therapeutic use | en |
| dc.subject | Middle Aged | en |
| dc.subject | Pain Measurement | en |
| dc.subject | Pilot Projects | en |
| dc.subject | Receptors, Serotonin/*drug effects | en |
| dc.subject | Receptors, Serotonin, 5-HT3 | en |
| dc.subject | Serotonin Antagonists/*therapeutic use | en |
| dc.subject | Treatment Outcome | en |
| dc.title | Treatment of fibromyalgia with tropisetron, a 5HT3 serotonin antagonist: a pilot study | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/10752491 | - |
| heal.identifier.secondary | http://www.springerlink.com/content/dg31qn6l6kat56hq/fulltext.pdf | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2000 | - |
| heal.abstract | In this pilot study we investigated 10 women suffering from primary fibromyalgia. All patients received 5 mg of tropisetron in the evening, for a period of 4 weeks. Clinical disease variables included the measurement of a pain score, fatigue, sleep disturbances and measurement of the number of tender points. Five of our patients (50%) showed a statistical clinical improvement of all the above parameters starting after the first week of treatment. Two patients did not respond to the therapy and three discontinued the study because of side-effects. We conclude that administration of tropisetron in fibromyalgia patients could be useful in the management of this difficult and incurable syndrome. | en |
| heal.journalName | Clin Rheumatol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Papadopoulos-2000-Treatment of fibromy.pdf | 22.42 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
